Modulation of the local neutrophil response by a novel hyaluronic acid-binding peptide reduces bacterial burden during staphylococcal wound infection.

Infection and Immunity
Jerry C LeeRachel M McLoughlin

Abstract

Novel approaches targeting the host's immune response to treat Staphylococcus aureus infections have significant potential to improve clinical outcomes, in particular during infection with antibiotic-resistant strains. The hyaluronic acid-binding peptide (HABP) PEP35 was assessed for its ability to treat S. aureus infections using a clinically relevant murine model of surgical wound infection. PEP35 demonstrated no direct antimicrobial activity against a range of antibiotic-susceptible and antibiotic-resistant clinical isolates of Staphylococcus aureus. However, when this peptide was administered at the onset of infection and up to 4 h postchallenge with a methicillin-susceptible (MSSA) or a methicillin-resistant (MRSA) strain of S. aureus, it significantly reduced the bacterial burden at the wound infection site. PEP35 reduced the tissue bacterial burden by exclusively modulating the local neutrophil response. PEP35 administration resulted in a significant early increase in local CXCL1 and CXCL2 production, which resulted in a more rapid influx of neutrophils to the infection site. Importantly, neutrophil influx was not sustained after treatment with PEP35, and administration of PEP35 alone did not induce a local inflammatory ...Continue Reading

References

Sep 20, 2000·The Journal of Experimental Medicine·M E MummertA Takashima
Jul 20, 2001·The Journal of Hospital Infection·P AstagneauUNKNOWN INCISO Network Study Group
Oct 13, 2001·Laboratory Investigation; a Journal of Technical Methods and Pathology·J C MorelA E Koch
Mar 22, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Brian EndlichThomas A Hamilton
Oct 3, 2002·Nature Reviews. Immunology·Qiutang Li, Inder M Verma
Apr 4, 2003·The New England Journal of Medicine·Soju ChangUNKNOWN Vancomycin-Resistant Staphylococcus aureus Investigative Team
Sep 10, 2003·Journal of Leukocyte Biology·Margherita Zanetti
Sep 18, 1964·Science·R B KUNDSINP MORIN
May 18, 2004·Trends in Immunology·Giuseppina Bonizzi, Michael Karin
Mar 19, 2005·The Journal of Infectious Diseases·Lauren RiceJon A Buras
Mar 10, 2006·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·P C Appelbaum
Jun 1, 2006·Biopolymers·Nannette Y YountMichael R Yeaman
Jun 6, 2006·The Journal of Allergy and Clinical Immunology·Suzanne ZuyderduynKlaus F Rabe
Jun 28, 2006·Proceedings of the National Academy of Sciences of the United States of America·Rachel M McLoughlinJean C Lee
Aug 22, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Masahito HashimotoFriedrich Götz
Oct 27, 2006·Antimicrobial Agents and Chemotherapy·Kathleen J ZaleskiArthur O Tzianabos
Nov 23, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sarah C Mullaly, Paul Kubes
Dec 13, 2006·Nature Biotechnology·Robert E W Hancock, Hans-Georg Sahl
Jan 24, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Steven R BeatySun-Sang J Sung
Feb 22, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sonja von AulockCorinna Hermann
Mar 27, 2007·Nature Biotechnology·Monisha G ScottRobert E W Hancock
Aug 31, 2007·FEMS Immunology and Medical Microbiology·Victoria KostenkoRobert John Martinuzzi
Mar 7, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Hidetada KawanaKenichi Harigaya
Mar 7, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Katia De FilippoNancy Hogg
Jun 7, 2008·Cellular and Molecular Life Sciences : CMLS·L VerstrepenR Beyaert
Jul 9, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Rachel M McLoughlinArthur O Tzianabos
Oct 22, 2008·Annual Review of Pathology·Grace ChenGabriel Nuñez
Nov 13, 2008·Current Opinion in Biotechnology·Pamela HamillRobert E W Hancock
Jan 14, 2009·Infection and Immunity·Hitesh S DeshmukhVance G Fowler
Mar 24, 2009·Annual Review of Immunology·Sivakumar Vallabhapurapu, Michael Karin
Jun 23, 2009·Proceedings of the National Academy of Sciences of the United States of America·Petr HruzLars Eckmann
Aug 18, 2009·Trends in Biotechnology·Donna M EastonRobert E W Hancock
Mar 2, 2010·The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Médicale·Kevin B Laupland, David N Fisman

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Related Papers

Indian Journal of Dental Research : Official Publication of Indian Society for Dental Research
Rajvir MalikD K Suresh
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
Anselmo Jesus Otero-GonzálezOctávio Luiz Franco
Antimicrobial Agents and Chemotherapy
J Andy Tincu, Steven W Taylor
© 2021 Meta ULC. All rights reserved